FDA Considering Drug/Companion IVD Review Policy

In a new draft guidance, FDA suggests drug and IVD companion Dx developers with dependent tests apply for review concurrently.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories